查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2094228

代謝體學市場－2026-2032年全球市場預測

Metabolomics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，代謝體學市場將成長至 73.9 億美元，複合年成長率為 11.76%。

主要市場統計數據
基準年 2025 33.9億美元
預計年份：2026年 37.8億美元
預測年份 2032 73.9億美元
複合年成長率 (%) 11.76%

代謝體學執行摘要

代謝體學正成為系統生物學、精準醫學、藥物研發、營養科學、毒理學、農業和環境健康等領域的重要支柱。透過測量反映生物化學活性的小分子，代謝體學能夠動態地揭示表現型、疾病進展、治療反應、暴露效應和細胞代謝等資訊。與通常說明生物潛能的基因組數據不同，代謝體學分析能夠捕捉受基因、微生物群活性、飲食、藥物、生活方式和環境等因素影響的即時生物化學結果。

代謝體學領域的變革性變化

代謝體學領域正從探索性研究轉向應用決策支援工作流程，其應用範圍涵蓋醫療保健、生物技術、食品系統和環境科學等領域。實驗室正日益將代謝體學整合到縱向隊列研究、臨床試驗、流行病學、毒性篩檢以及生物製造製程最佳化中，而不再局限於單一代謝物的分析。這一轉變得益於儀器靈敏度的提高、頻譜庫的擴展、層析法解析度的增強以及自動化樣品製備技術的廣泛應用。

人工智慧對代謝體學的累積影響

人工智慧 (AI) 正在透過改進數據處理、代謝物註釋、代謝通路解讀和預測建模來重塑代謝體學。代謝體學資料集極為複雜，包含數千個頻譜特徵，這些特徵會受到生物變異性、技術雜訊、基質效應、離子抑制、缺失值、批次效應和保留時間偏移等因素的影響。人工智慧演算法正擴大被用於輔助峰值檢測、頻譜反捲積、特徵對齊、噪音降低和品管評估，從而幫助研究人員提高分析的一致性。

代謝體學系統中的關鍵區域見解

在亞太地區，代謝體學活動受益於不斷擴大的生物醫學研究基礎設施、國家對精準醫療的投入、日益增強的臨床研究能力，以及對營養、農業和傳統醫學現代化的濃厚興趣。中國、日本、韓國、印度、新加坡和澳洲在亞太地區的代謝體學相關出版物、生物樣本庫建立和多組體學研究中發揮核心作用。該地區龐大的人口基數和高度的遺傳多樣性為進行人群規模的代謝研究提供了機會。同時，心血管代謝疾病負擔的日益加重，推動了對與糖尿病、肥胖、肝病、心血管疾病風險和飲食變化相關的生物標記的需求。

來自影響代謝體學傳播的關鍵群體的見解

東南亞國協正透過生物醫學研究、食品科學、天然產物發現、感染疾病研究和農業生物技術等途徑，日益重視代謝體學。新加坡已成為精準醫療和多體學研究的區域中心，而泰國、馬來西亞、印尼、越南和菲律賓則在熱帶疾病、營養、生物多樣性和作物科學等領域進行研究。該地區多樣化的飲食、微生物群和環境暴露為代謝譜分析創造了重要的科學價值，尤其是在統一方案和區域培訓網路的支持下。

主要國家代謝體學學研究及應用趨勢

美國是代謝體學研究的中心，擁有大規模學術醫療中心、臨床試驗網路、藥物研發機構、公共資料儲存庫和最先進的儀器核心設施。加拿大透過人口健康調查、營養科學、環境健康和多組體學計畫做出貢獻，而墨西哥則在代謝性疾病、感染疾病、食品科學和農業研究領域推動代謝體學的發展。在拉丁美洲，巴西在生物多樣性、天然產物、作物改良、熱帶疾病研究和生物醫學代謝體學學方面表現突出。

代謝體學領域領導者的實用建議

產業領導者在擴大代謝體學計畫規模之前，應優先考慮分析的嚴謹性。標準化的檢體採集、儲存、萃取、儀器校準、內標、混合品管檢體和批次校正程序對於產生可重複的代謝體學學數據至關重要。各機構應記錄分析前變量，例如空腹狀態、藥物狀況、飲食、晝夜節律、檢體基質和儲存時間，因為這些因素會對代謝物譜產生顯著影響。

基於證據的代謝體學見解的調查方法

穩健的代謝體學調查方法始於明確的研究目標、明確的生物學挑戰和合適的實驗設計。在樣本分析之前，必須規劃好隊列選擇、樣本大小計算、隨機化、盲法、對照組設定、混雜因素的識別。關鍵元資料包括年齡、性別、疾病狀態、藥物暴露、飲食、空腹狀態、體力活動、採樣時間、儲存條件和樣本處理細節。

結論

代謝體學正從一個專門的分析領域發展成為精準醫療、生物標記發現、藥物研發、營養科學、環境健康和農業創新等領域的策略驅動力。其價值在於能夠即時捕捉生化活動，並將分子訊號轉化為對健康、疾病、暴露和生物功能具有實際意義的見解。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章代謝體學市場：依成分分類

  • 生物資訊學工具和服務
    • 生物資訊服務
    • 生物資訊工具和資料庫
  • 代謝體學學設備
    • 檢測工具
      • 質譜分析
      • 核磁共振波譜
      • 表面質譜法
    • 分離工具
      • 毛細管電泳
      • 氣相層析法
      • 高效液相層析
      • 超高效液相層析法

第8章代謝體學市場：依分析法分類

  • 非標靶代謝體學
  • 半標靶代謝體學
  • 標靶代謝體學
  • 穩定同位素示踪和通量體學
  • 空間代謝體學

第9章代謝體學市場：依樣本類型分類

  • 人體體液
    • 血液、血漿和血清
    • 尿
    • 腦脊髓液
    • 唾液
    • 呼出的冷凝液和呼出的
  • 動物和臨床前樣本
  • 植物和農業樣品
  • 食品和飲料樣品
  • 環境樣品

第10章：代謝體學市場：依適應症分類

  • 心血管疾病
  • 代謝性疾病
  • 神經病變
  • 腫瘤性疾病

第11章代謝體學市場：按應用領域分類

  • 生物標記發現
    • 癌症生物標記
    • 神經系統生物標記
  • 藥物發現
    • 代謝途徑
    • 目標識別
  • 環境科學
    • 農藥殘留分析
    • 水質分析
  • 營養基因體學
    • 心血管健康
    • 肥胖調查
  • 個人化醫療
    • 基因組研究
    • 治療監測
  • 毒性測試

第12章代謝體學市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 製藥和生物技術公司

第13章代謝體學市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章代謝體學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章代謝體學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Advanced Chemistry Development, Inc.
  • Advion, Inc.
  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Cayman Chemical Company
  • Cerno Bioscience LLC
  • Chenomx Inc.
  • Clinical Microbiomics A/S
  • GERSTEL GmbH & Co. KG
  • Hitachi High-Tech Corporation
  • Human Metabolome Technologies, Inc.
  • JEOL Ltd.
  • LECO Corporation
  • Lipotype GmbH
  • Merck KGaA
  • Mestrelab Research SL
  • Metabolon, Inc.
  • metaSysX GmbH
  • Nightingale Health Plc
  • numares AG
  • Owlstone Medical Limited
  • Oxford Instruments plc
  • QIAGEN NV
  • Restek Corporation
  • Revvity, Inc.
  • Sapient Bioanalytics, LLC
  • SCION Instruments NL BV
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-50124643847C

The Metabolomics Market is projected to grow by USD 7.39 billion at a CAGR of 11.76% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.39 billion
Estimated Year [2026] USD 3.78 billion
Forecast Year [2032] USD 7.39 billion
CAGR (%) 11.76%

Metabolomics Executive Summary

Metabolomics is becoming a critical pillar of systems biology, precision medicine, pharmaceutical research, nutrition science, toxicology, agriculture, and environmental health. By measuring small-molecule metabolites that reflect biochemical activity, metabolomics provides a dynamic view of phenotype, disease progression, treatment response, exposure effects, and cellular metabolism. Unlike genomic data, which often describes biological potential, metabolomic profiling captures real-time biochemical outcomes shaped by genes, microbiome activity, diet, drugs, lifestyle, and environment.

The field is advancing through high-resolution mass spectrometry, nuclear magnetic resonance spectroscopy, liquid chromatography, gas chromatography, capillary electrophoresis, stable isotope tracing, and increasingly sophisticated bioinformatics. Targeted metabolomics is widely used for precise quantification of defined metabolic pathways, while untargeted metabolomics enables broad biomarker discovery and pathway exploration. The growing integration of metabolomics with genomics, transcriptomics, proteomics, lipidomics, microbiomics, exposomics, and clinical data is accelerating multi-omics research and strengthening the role of metabolic biomarkers in translational science.

Key demand drivers include the need for earlier disease detection, better patient stratification, biomarker validation, drug safety assessment, antimicrobial resistance research, metabolic disease monitoring, cancer biology, neurodegenerative disease studies, and food quality testing. At the same time, the industry faces persistent challenges around analytical reproducibility, metabolite annotation, data harmonization, reference standards, sample preparation variability, and regulatory acceptance of metabolomics-derived biomarkers. Organizations that prioritize standardized workflows, interoperable datasets, robust quality control, and clinically relevant validation are positioned to extract the highest value from metabolomics technologies.

Transformative Shifts in the Metabolomics Landscape

The metabolomics landscape is shifting from exploratory research toward applied, decision-support workflows across healthcare, biotechnology, food systems, and environmental sciences. Laboratories are moving beyond standalone metabolite profiling and increasingly embedding metabolomics into longitudinal cohort studies, clinical trials, epidemiology, toxicology screening, and biomanufacturing process optimization. This transition is supported by improved instrument sensitivity, expanded spectral libraries, enhanced chromatographic resolution, and greater adoption of automated sample preparation.

A major transformation is the convergence of metabolomics with multi-omics and real-world data. Researchers are combining metabolic signatures with genomic variants, protein expression, microbiome profiles, imaging, electronic health records, and environmental exposure datasets to identify mechanisms of disease and therapeutic response. This is particularly important in oncology, cardiometabolic disorders, rare diseases, immune-mediated conditions, and neurological research, where metabolic pathway changes can provide actionable biological context.

Another defining shift is the growing emphasis on standardization and reproducibility. International scientific communities and public repositories have encouraged common reporting practices, metadata capture, quality-control samples, retention time indexing, and confidence levels for metabolite identification. These practices are improving comparability across studies and strengthening the credibility of metabolomics evidence.

The technology base is also diversifying. High-resolution LC-MS remains central for broad coverage of polar and non-polar metabolites, GC-MS continues to support volatile and derivatized compound analysis, NMR contributes strong reproducibility and quantitative reliability, and ion mobility separation is improving isomer resolution. Together, these advances are enabling deeper pathway coverage and more confident metabolic interpretation.

Cumulative Impact of Artificial Intelligence on Metabolomics

Artificial intelligence is reshaping metabolomics by improving data processing, metabolite annotation, pathway interpretation, and predictive modeling. Metabolomics datasets are complex because they contain thousands of spectral features influenced by biological variation, technical noise, matrix effects, ion suppression, missing values, batch effects, and retention time shifts. AI-enabled algorithms are increasingly used to support peak detection, spectral deconvolution, feature alignment, noise reduction, and quality-control assessment, helping researchers improve analytical consistency.

Machine learning is also strengthening biomarker discovery by identifying metabolic patterns associated with disease states, treatment response, toxic exposures, nutritional status, and microbial metabolism. Supervised learning models can classify samples or predict outcomes based on metabolite panels, while unsupervised approaches help reveal hidden biochemical subgroups. Deep learning is being explored for mass spectral prediction, molecular structure inference, and annotation of unknown metabolites, a long-standing limitation in untargeted metabolomics.

The cumulative impact of AI is most significant when it is combined with curated spectral libraries, high-quality metadata, and biological validation. AI can accelerate hypothesis generation, but metabolomics findings still require rigorous experimental design, independent validation, and biochemical interpretation. In regulated or clinical contexts, explainability, traceability, model performance monitoring, and bias assessment remain essential.

As metabolomics becomes more integrated into precision health and pharmaceutical research, AI is supporting faster translation from raw spectra to biologically meaningful insights. The strongest applications combine automated analytics with domain expertise in biochemistry, analytical chemistry, clinical science, and computational biology.

Key Regional Insights Across the Metabolomics Ecosystem

In Asia-Pacific, metabolomics activity is supported by expanding biomedical research infrastructure, national investments in precision medicine, growing clinical research capacity, and strong interest in nutrition, agriculture, and traditional medicine modernization. China, Japan, South Korea, India, Singapore, and Australia are central contributors to regional metabolomics publications, biobanking initiatives, and multi-omics research. The region's large and genetically diverse populations create opportunities for population-scale metabolic studies, while rising cardiometabolic disease burdens increase demand for biomarkers linked to diabetes, obesity, liver disease, cardiovascular risk, and dietary transitions.

North America remains one of the most advanced regions for metabolomics adoption due to extensive academic research networks, mature pharmaceutical and biotechnology ecosystems, large-scale cohort studies, clinical trial activity, and widespread use of high-resolution mass spectrometry platforms. The United States and Canada are prominent in precision medicine, cancer metabolism, microbiome-metabolome integration, exposomics, and drug development applications. Public research funding, data repositories, and institutional core facilities continue to support high-throughput metabolomics workflows and cross-disciplinary collaboration.

Latin America is gaining relevance through growing research in infectious diseases, tropical medicine, agriculture, food authenticity, environmental monitoring, and metabolic disorders. Brazil and Mexico are particularly important regional contributors, supported by universities, public health research, and agricultural science programs. The region's biodiversity, dietary diversity, and infectious disease profile provide distinctive opportunities for metabolomics studies, although access to advanced analytical infrastructure and trained bioinformatics specialists remains uneven.

Europe has a strong foundation in metabolomics through established research consortia, biobanks, population cohorts, clinical research networks, and regulatory science capabilities. Countries across Western and Northern Europe are active in multi-omics integration, nutritional epidemiology, rare disease studies, drug safety assessment, and environmental exposure research. European data protection rules and quality standards are shaping responsible metabolomics data governance, while collaborative research frameworks help advance reproducibility and cross-border scientific exchange.

The Middle East is increasingly investing in genomics, precision health, diabetes research, and population health programs, creating a stronger pathway for metabolomics adoption. Countries in the Gulf are focusing on metabolic disorders, inherited diseases, nutrition, and personalized healthcare, areas where metabolite profiling can add significant value. Regional needs are influenced by high prevalence of diabetes and obesity, consanguinity-related genetic conditions, and growing interest in preventive health systems.

Africa presents important opportunities for metabolomics in infectious disease research, maternal and child health, nutrition, environmental exposure assessment, agriculture, and neglected tropical disease studies. South Africa has comparatively stronger analytical chemistry and biomedical research capacity, while broader continental efforts are expanding through research collaborations and public health initiatives. The region's biological diversity, disease burden, and environmental variability make metabolomics highly relevant, but sustainable progress depends on instrumentation access, workforce development, sample logistics, and local data infrastructure.

Key Group Insights Shaping Metabolomics Adoption

ASEAN countries are building metabolomics relevance through biomedical research, food science, natural product discovery, infectious disease studies, and agricultural biotechnology. Singapore has positioned itself as a regional hub for precision medicine and multi-omics research, while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines contribute to research in tropical diseases, nutrition, biodiversity, and crop science. The region's diverse diets, microbiomes, and environmental exposures create strong scientific value for metabolic profiling, particularly when supported by harmonized protocols and regional training networks.

The GCC is increasingly linking metabolomics with national health priorities, especially diabetes, obesity, cardiovascular disease, inherited metabolic disorders, and precision medicine. High investment in healthcare infrastructure, digital health, and genomics programs provides a foundation for integrating metabolite profiling into preventive and personalized care models. Metabolomics can be particularly valuable in understanding cardiometabolic risk in populations experiencing rapid lifestyle transitions, while also supporting nutrition research and biomarker studies in regional cohorts.

The European Union benefits from coordinated research frameworks, cross-border scientific infrastructure, regulatory alignment, and strong emphasis on data governance. EU-based metabolomics activity spans clinical biomarker discovery, food safety, exposomics, environmental health, toxicology, and pharmaceutical research. The region's policies on data protection, ethical research, and quality systems are influencing best practices for metabolomics data handling, particularly in studies that combine molecular profiles with health records and biobank data.

BRICS economies collectively represent a significant base for metabolomics research because of large populations, diverse disease burdens, expanding biotechnology capacity, and strong agricultural and environmental science needs. China and India contribute scale and growing multi-omics capabilities, Brazil adds biodiversity and agricultural metabolomics strength, Russia contributes analytical chemistry and biomedical research capacity, and South Africa provides an important platform for infectious disease and population health research. Collaboration across these economies can improve representation of non-Western populations in metabolomic reference datasets.

G7 countries are at the forefront of metabolomics adoption due to mature life science research systems, advanced analytical instrumentation, pharmaceutical development, population cohorts, and clinical research infrastructure. These countries are active in cancer metabolism, metabolic disease, aging, nutrition, toxicology, and regulatory science. Their scientific output and technical standards often shape global practices in sample preparation, quality assurance, metabolite annotation, and data sharing.

NATO member countries include many leading contributors to biomedical research, defense-related toxicology, environmental exposure science, infectious disease preparedness, and advanced analytical chemistry. Within this grouping, metabolomics supports research on chemical exposure, human performance, trauma response, pathogen-host interactions, and personalized medicine. Strong academic networks and shared scientific standards enable collaboration, although national regulatory frameworks and data governance requirements influence implementation models.

Key Country Insights in Metabolomics Research and Application

The United States is a central hub for metabolomics research, supported by extensive academic medical centers, clinical trial networks, pharmaceutical research, public data repositories, and advanced instrument core facilities. Canada contributes through population health research, nutrition science, environmental health, and multi-omics programs, while Mexico is advancing metabolomics in metabolic disease, infectious disease, food science, and agricultural research. In Latin America, Brazil stands out for work in biodiversity, natural products, crop improvement, tropical disease research, and biomedical metabolomics.

The United Kingdom has a strong position in population-scale health studies, biobanks, epidemiology, cancer research, and analytical chemistry. Germany is notable for metabolomics infrastructure, systems biology, pharmaceutical research, environmental health, and clinical biomarker discovery. France contributes across nutrition, microbiome research, toxicology, clinical metabolomics, and food quality applications. Russia has expertise in analytical chemistry, biomedical research, and systems biology, while Italy and Spain are active in nutrition, cardiometabolic disease, oncology, microbiome-metabolome research, and agricultural applications.

China has rapidly expanded its metabolomics capabilities through large research investments, hospital-based studies, agricultural science, precision medicine, and high-throughput analytical platforms. India is increasingly applying metabolomics to diabetes, tuberculosis, cancer, nutrition, traditional medicine, and crop science, supported by a growing biotechnology and bioinformatics talent base. Japan remains a leader in high-quality analytical science, metabolic pathway research, aging studies, and precision health applications. Australia contributes through strong capabilities in population health, nutrition, environmental exposure assessment, plant science, and clinical research. South Korea is advancing metabolomics through precision medicine, cancer research, microbiome studies, biotechnology, and digital health integration.

Across these countries, the common pattern is a shift from isolated metabolite measurement toward integrated metabolomic intelligence. National strengths differ by disease priorities, research funding, instrument access, biobank maturity, and computational infrastructure, but all major economies are increasingly treating metabolomics as a strategic tool for biomarker discovery, pathway analysis, therapeutic development, food system innovation, and public health research.

Actionable Recommendations for Metabolomics Leaders

Industry leaders should prioritize analytical rigor before scaling metabolomics programs. Standardized sample collection, storage, extraction, instrument calibration, internal standards, pooled quality-control samples, and batch correction procedures are essential for generating reproducible metabolomics data. Organizations should document pre-analytical variables such as fasting status, medication use, diet, circadian timing, sample matrix, and storage duration because these factors can materially influence metabolite profiles.

Decision-makers should also invest in interoperable data infrastructure. Metabolomics value increases when datasets can be connected with genomics, proteomics, microbiome profiles, clinical records, imaging, exposure data, and longitudinal outcomes. Structured metadata, controlled vocabularies, secure data environments, and FAIR data principles improve reuse and strengthen scientific credibility.

For biomarker programs, leaders should distinguish between discovery, verification, validation, and clinical utility assessment. Untargeted metabolomics can identify candidate metabolic signatures, but targeted quantitative assays, independent cohorts, biological plausibility, and performance testing are needed before operational deployment. In drug development, metabolomics should be embedded early in pharmacodynamics, toxicity assessment, patient stratification, and mechanism-of-action studies.

Organizations adopting AI should treat model governance as a core requirement. Algorithms should be trained on high-quality data, validated across independent datasets, monitored for drift, and interpreted with biochemical expertise. Explainable AI approaches can improve confidence among clinicians, regulators, and research stakeholders.

Finally, leaders should build multidisciplinary teams that include analytical chemists, biochemists, clinicians, bioinformaticians, statisticians, regulatory experts, and domain specialists. Metabolomics is most powerful when technical excellence is paired with clear biological questions and actionable decision pathways.

Research Methodology for Evidence-Based Metabolomics Insights

A robust metabolomics research methodology begins with clear study objectives, defined biological questions, and fit-for-purpose experimental design. Cohort selection, sample size justification, randomization, blinding, control groups, and confounder capture should be planned before sample analysis. Critical metadata include age, sex, disease status, medication exposure, diet, fasting state, physical activity, collection time, storage conditions, and sample processing details.

Analytical workflows typically involve sample preparation followed by LC-MS, GC-MS, NMR, capillary electrophoresis-MS, or complementary platform combinations. Targeted metabolomics uses authentic standards, calibration curves, and predefined analyte panels to generate quantitative results. Untargeted metabolomics uses broad-spectrum acquisition to detect as many features as possible, followed by feature extraction, alignment, normalization, annotation, statistical analysis, and pathway interpretation.

Quality assurance is central to credible metabolomics. Best practices include randomized injection order, pooled quality-control samples, system suitability checks, internal standards, blank samples, replicate analyses, retention time monitoring, signal drift correction, and documented acceptance criteria. Metabolite identification confidence should be reported transparently, distinguishing confirmed compounds from putatively annotated features.

Data analysis should combine univariate statistics, multivariate modeling, pathway enrichment, network analysis, and biological interpretation. AI and machine learning may be used for classification or prediction, but models require independent validation, performance metrics, and assessment of overfitting. Findings should be validated through targeted assays, orthogonal platforms, external cohorts, or mechanistic experiments when possible.

Ethical and data governance considerations are particularly important when metabolomics is linked with human health data. Secure storage, consent alignment, privacy protection, and responsible sharing practices support trust and regulatory compliance.

Conclusion

Metabolomics is evolving from a specialized analytical discipline into a strategic engine for precision medicine, biomarker discovery, drug development, nutrition science, environmental health, and agricultural innovation. Its value lies in the ability to capture real-time biochemical activity and translate molecular signals into practical insights about health, disease, exposure, and biological function.

The strongest momentum is coming from multi-omics integration, improved analytical platforms, AI-enabled data interpretation, and rising demand for validated metabolic biomarkers. Regional and country-level adoption patterns reflect differences in research infrastructure, disease priorities, biobank capacity, and digital health maturity, but the global direction is consistent: metabolomics is becoming more standardized, more computationally enabled, and more closely linked to applied decision-making.

To succeed, organizations must avoid treating metabolomics as a standalone measurement exercise. Sustainable impact requires rigorous study design, harmonized workflows, validated assays, high-quality metadata, secure data integration, and multidisciplinary interpretation. When implemented with scientific discipline and clear use cases, metabolomics can materially improve understanding of disease mechanisms, therapeutic response, nutritional biology, environmental exposure, and population health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Metabolomics Market, by Component

  • 7.1. Introduction
  • 7.2. Bioinformatics Tools & Services
    • 7.2.1. Bioinformatics Services
    • 7.2.2. Bioinformatics Tools & Databases
  • 7.3. Metabolomic Instruments
    • 7.3.1. Detection Tools
      • 7.3.1.1. Mass Spectrometry
      • 7.3.1.2. Nuclear Magnetic Resonance Spectroscopy
      • 7.3.1.3. Surface-based Mass Analysis
    • 7.3.2. Separation Tools
      • 7.3.2.1. Capillary Electrophoresis
      • 7.3.2.2. Gas Chromatography
      • 7.3.2.3. High-Performance Liquid Chromatography
      • 7.3.2.4. Ultra Performance Liquid Chromatography

8. Metabolomics Market, by Analytical Approach

  • 8.1. Introduction
  • 8.2. Untargeted Metabolomics
  • 8.3. Semi-Targeted Metabolomics
  • 8.4. Targeted Metabolomics
  • 8.5. Stable-Isotope Tracing And Fluxomics
  • 8.6. Spatial Metabolomics

9. Metabolomics Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Human Biofluids
    • 9.2.1. Blood, Plasma, And Serum
    • 9.2.2. Urine
    • 9.2.3. Cerebrospinal Fluid
    • 9.2.4. Saliva
    • 9.2.5. Breath Condensate And Exhaled Breath
  • 9.3. Animal And Preclinical Samples
  • 9.4. Plant And Agricultural Samples
  • 9.5. Food And Beverage Samples
  • 9.6. Environmental Samples

10. Metabolomics Market, by Indication

  • 10.1. Introduction
  • 10.2. Cardiovascular Disorders
  • 10.3. Metabolic Disorders
  • 10.4. Neurological Disorders
  • 10.5. Oncological Disorders

11. Metabolomics Market, by Application

  • 11.1. Introduction
  • 11.2. Biomarker Discovery
    • 11.2.1. Cancer Biomarkers
    • 11.2.2. Neurological Biomarkers
  • 11.3. Drug Discovery
    • 11.3.1. Metabolic Pathways
    • 11.3.2. Target Identification
  • 11.4. Environmental Science
    • 11.4.1. Pesticide Residue Analysis
    • 11.4.2. Water Quality Analysis
  • 11.5. Nutrigenomics
    • 11.5.1. Cardiovascular Health
    • 11.5.2. Obesity Research
  • 11.6. Personalized Medicine
    • 11.6.1. Genomic Studies
    • 11.6.2. Therapeutic Monitoring
  • 11.7. Toxicology Testing

12. Metabolomics Market, by End-User

  • 12.1. Introduction
  • 12.2. Academic Research Institutes
  • 12.3. Contract Research Organizations
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Metabolomics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Metabolomics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Metabolomics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Advanced Chemistry Development, Inc.
  • 17.2. Advion, Inc.
  • 17.3. Agilent Technologies, Inc.
  • 17.4. Bruker Corporation
  • 17.5. Cayman Chemical Company
  • 17.6. Cerno Bioscience LLC
  • 17.7. Chenomx Inc.
  • 17.8. Clinical Microbiomics A/S
  • 17.9. GERSTEL GmbH & Co. KG
  • 17.10. Hitachi High-Tech Corporation
  • 17.11. Human Metabolome Technologies, Inc.
  • 17.12. JEOL Ltd.
  • 17.13. LECO Corporation
  • 17.14. Lipotype GmbH
  • 17.15. Merck KGaA
  • 17.16. Mestrelab Research S.L.
  • 17.17. Metabolon, Inc.
  • 17.18. metaSysX GmbH
  • 17.19. Nightingale Health Plc
  • 17.20. numares AG
  • 17.21. Owlstone Medical Limited
  • 17.22. Oxford Instruments plc
  • 17.23. QIAGEN N.V.
  • 17.24. Restek Corporation
  • 17.25. Revvity, Inc.
  • 17.26. Sapient Bioanalytics, LLC
  • 17.27. SCION Instruments NL B.V.
  • 17.28. Shimadzu Corporation
  • 17.29. Thermo Fisher Scientific Inc.
  • 17.30. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL METABOLOMICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL METABOLOMICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL METABOLOMICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL METABOLOMICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL METABOLOMICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL METABOLOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL METABOLOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL METABOLOMICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL METABOLOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOINFORMATICS TOOLS & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOINFORMATICS TOOLS & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOINFORMATICS TOOLS & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOINFORMATICS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOINFORMATICS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOINFORMATICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOINFORMATICS TOOLS & DATABASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOINFORMATICS TOOLS & DATABASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOINFORMATICS TOOLS & DATABASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METABOLOMIC INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METABOLOMIC INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METABOLOMIC INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DETECTION TOOLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DETECTION TOOLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DETECTION TOOLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SURFACE-BASED MASS ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SURFACE-BASED MASS ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SURFACE-BASED MASS ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SEPARATION TOOLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEPARATION TOOLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SEPARATION TOOLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAPILLARY ELECTROPHORESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAPILLARY ELECTROPHORESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAPILLARY ELECTROPHORESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GAS CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GAS CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GAS CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UNTARGETED METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UNTARGETED METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UNTARGETED METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEMI-TARGETED METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SEMI-TARGETED METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEMI-TARGETED METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STABLE-ISOTOPE TRACING AND FLUXOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STABLE-ISOTOPE TRACING AND FLUXOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STABLE-ISOTOPE TRACING AND FLUXOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SPATIAL METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SPATIAL METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SPATIAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN BIOFLUIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN BIOFLUIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN BIOFLUIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD, PLASMA, AND SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD, PLASMA, AND SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD, PLASMA, AND SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREATH CONDENSATE AND EXHALED BREATH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BREATH CONDENSATE AND EXHALED BREATH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREATH CONDENSATE AND EXHALED BREATH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL AND PRECLINICAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL AND PRECLINICAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL AND PRECLINICAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLANT AND AGRICULTURAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PLANT AND AGRICULTURAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLANT AND AGRICULTURAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FOOD AND BEVERAGE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FOOD AND BEVERAGE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FOOD AND BEVERAGE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENVIRONMENTAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENVIRONMENTAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENVIRONMENTAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL METABOLIC PATHWAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL METABOLIC PATHWAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL METABOLIC PATHWAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ENVIRONMENTAL SCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENVIRONMENTAL SCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ENVIRONMENTAL SCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PESTICIDE RESIDUE ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PESTICIDE RESIDUE ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PESTICIDE RESIDUE ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL WATER QUALITY ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL WATER QUALITY ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL WATER QUALITY ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NUTRIGENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NUTRIGENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NUTRIGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOVASCULAR HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOVASCULAR HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOVASCULAR HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL OBESITY RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL OBESITY RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL OBESITY RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENOMIC STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GENOMIC STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENOMIC STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 283. GCC METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. GCC METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 285. GCC METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 286. GCC METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 290. GCC METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 292. GCC METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. GCC METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. GCC METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 295. GCC METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 296. GCC METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 297. GCC METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 298. GCC METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 299. GCC METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 334. G7 METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 335. G7 METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 336. G7 METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 337. G7 METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 338. G7 METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 339. G7 METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 340. G7 METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 341. G7 METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. G7 METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 343. G7 METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 344. G7 METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 345. G7 METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 346. G7 METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 347. G7 METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 348. G7 METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 349. G7 METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 350. G7 METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 351. NATO METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 352. NATO METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 353. NATO METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 354. NATO METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 355. NATO METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 356. NATO METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 357. NATO METABOLOMICS MARKET SIZE, BY ANALYTICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 358. NATO METABOLOMICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 359. NATO METABOLOMICS MARKET SIZE, BY HUMAN BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 360. NATO METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 361. NATO METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 362. NATO METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 363. NATO METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 364. NATO METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 365. NATO METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 366. NATO METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (U